Overview

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Status:
Active, not recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Centre Antoine Lacassagne

Collaborator:

GlaxoSmithKline

Treatments:

Temozolomide